secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001437749-25-001006
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences appoints Paul LaViolette as CEO; grants 1.5M stock options with revenue/market cap milestones
--------------------------------------------------------------------------------

- Paul LaViolette, former Co-Chairman, becomes CEO and President effective Jan 9, 2025.
- Employment: $725k base salary, 70% target bonus, and option to purchase 1.5M shares at $18.43.
- Options vest 30% time-based over 4 years; 70% performance-based tied to market cap ($3B–$9B) and GAAP revenue/margin targets.
- Company also granted inducement options for 138,800 shares to 11 new employees at $18.55.
- Pulse to present at JP Morgan Healthcare Conference Jan 15; nano-PFA cardiac systems in clinical studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/0001437749-25-001006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/plse20250109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-001006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer